The U.S. health and wellness devices market size is likely to be valued at US$123.0 billion in 2026, and is expected to reach US$222.0 billion by 2033, growing at a CAGR of 8.8% during the forecast period from 2026 to 2033, driven by the high prevalence of chronic diseases such as diabetes, cardiovascular disorders, and obesity, which increase demand for continuous health monitoring.

Strong adoption of wearable technologies and connected health devices supports preventive healthcare and personal wellness management. Expanding remote patient monitoring and hospital-at-home programs are accelerating the use of clinical-grade home health devices.

Driver- Rising Prevalence of Chronic Disease Creating Sustained Device Demand

The U.S. carries one of the highest chronic disease burdens among developed nations, a structural healthcare reality that creates durable, large-scale demand for health and wellness monitoring and management devices across both consumer and clinical channels. In May 2026, the CDC estimated that approximately 60% of American adults had at least one chronic condition, and 40% had two or more, with cardiovascular disease, type 2 diabetes, obesity, chronic respiratory disease, and hypertension representing the highest-prevalence conditions.

According to a 2025 article published in the CDC, the U.S. diabetes epidemic is particularly significant: approximately 38 million Americans live with diagnosed diabetes, and an additional 98 million adults have prediabetes, collectively defining a massive market for blood glucose monitoring devices, CGMs, and connected insulin delivery systems. DexCom's G-series CGMs and Abbott's FreeStyle Libre system have demonstrated the commercial scale achievable in this segment, with CGM adoption growing rapidly among both type 1 and type 2 diabetes patients.

Restraint - FDA Regulatory Complexity and Clinical Validation Requirements

The U.S. health and wellness device market operates under a complex FDA regulatory framework that distinguishes between general wellness devices exempt from FDA oversight, low-risk devices subject to 510(k) premarket notification, and higher-risk devices requiring De Novo classification or Premarket Approval (PMA). Obtaining and maintaining FDA clearance for clinical-grade wellness devices imposes significant time, cost, and technical validation burdens on manufacturers, particularly small and startup companies without existing FDA regulatory infrastructure.

The FDA's evolving guidance on software as a medical device (SaMD), clinical decision support software, and AI/ML-based health monitoring algorithms creates ongoing regulatory uncertainty for digital health and wellness device developers, as the boundary between general wellness software and regulated medical device software continues to be refined through FDA guidance documents and enforcement actions.

Opportunity - AI-Powered Health Analytics and Predictive Monitoring Integration

The integration of artificial intelligence and machine learning analytics into health and wellness device platforms represents the most significant near-term product innovation opportunity in the U.S. market. AI-powered health analytics capabilities, including anomaly detection in continuous physiological monitoring streams, predictive risk scoring for cardiovascular events and hypoglycemic episodes, and personalized health coaching algorithms, are transforming health and wellness devices from passive data collection tools into active clinical decision support systems that deliver actionable health insights to users and their care teams.

FDA's Digital Health Center of Excellence and its evolving Pre-Determined Change Control Plan (PCCP) guidance for AI/ML-based medical devices are progressively providing clearer regulatory pathways for adaptive AI health monitoring algorithms, enabling manufacturers to update and improve AI models post-market without requiring new device submissions. Companies that successfully integrate clinically validated AI analytics into wellness device platforms are positioned to command premium pricing, improve user engagement and retention, and establish defensible competitive advantages through proprietary health AI model development.

Product Type Insights

Wearable devices are projected to dominate the product type segment, accounting for approximately 38% of market revenue in 2026. The wearable health device segment encompasses smartwatches with integrated health sensors (ECG, blood oxygen, skin temperature, heart rate variability), dedicated fitness trackers, continuous glucose monitors worn on the body, cardiac patch monitors, and smart clothing with embedded biometric sensors. Apple Watch commands the largest single-product share within the wearable category, leveraging its FDA-cleared ECG and fall detection features to position the device as both a consumer lifestyle product and a clinically relevant health monitoring tool.

Medical devices for wellness are likely to be the fastest-growing product type segment, driven by CMS reimbursement expansion for remote physiological monitoring, the growing clinical adoption of home-use blood pressure monitors, CGMs, and cardiac event monitors in chronic disease management programs, and the increasing FDA clearance of novel connected medical devices designed for home wellness applications. Abbott has expanded the use of its FreeStyle Libre 3 continuous glucose monitoring (CGM) system, a FDA-cleared connected medical device that allows diabetes patients to monitor glucose levels in real time from home.

Application Insights

Chronic disease management is estimated to lead, accounting for approximately 35% of market revenue in 2026. The chronic disease management application encompasses continuous glucose monitoring for diabetes, blood pressure monitoring for hypertension, cardiac rhythm monitoring for arrhythmia detection, pulse oximetry for COPD and heart failure patients, and connected medication adherence devices for polypharmacy management. Dexcom is a leading provider of continuous glucose monitoring (CGM) systems for diabetes management. Its Dexcom G7 enables real-time glucose tracking, alerts for high and low glucose levels, and remote data sharing with caregivers and healthcare providers.

Mental health and stress relief represents the fastest-growing application segment within the market, driven by the escalating U.S. mental health crisis, growing consumer awareness of stress management and sleep quality as foundational health priorities, and the emergence of a new generation of devices specifically designed to monitor and manage mental wellbeing. Apollo Neuroscience developed the Apollo Neuro wearable, a device specifically designed to help users manage stress, improve sleep quality, and support mental well-being through neuroscience-based vibration therapy.

End-user Insights

Individual/Home users are anticipated to dominate the end-user segment, accounting for approximately 54% of the total share in 2026. The individual and home user segment encompasses both direct consumer purchase of wellness devices through retail, e-commerce, and direct-to-consumer brand channels, and patient-directed use of provider-prescribed medical wellness devices in the home setting. Apple Inc. has positioned the Apple Watch as a home-based health and wellness device used directly by consumers to monitor heart rate, ECG, sleep, blood oxygen, activity levels, and other health metrics.

Hospitals and clinics represent the fastest-growing end-user segment, driven by the institutional adoption of remote patient monitoring programs, hospital-at-home initiatives, and value-based care models that require continuous, clinical-grade patient monitoring infrastructure beyond the hospital building. Mayo Clinic has expanded its Advanced Care at Home program, which delivers hospital-level care in patients' homes through virtual care teams, remote vital-sign monitoring, and in-home clinical services.

The U.S. health and wellness devices market features a diverse competitive landscape spanning consumer electronics giants, dedicated medical device manufacturers, and specialist digital health companies, each competing across distinct product categories, regulatory tiers, and distribution channels. The market is characterized by a dual-track competitive dynamic: consumer electronics companies Apple, Samsung, Fitbit, and Garmin compete primarily on device design, ecosystem integration, brand equity, and retail distribution, while medical device companies Medtronic, Abbott, DexCom, OMRON, Philips, and GE HealthCare compete on clinical validation, FDA regulatory clearance portfolio, healthcare provider relationships, and reimbursement access.

Apple has established itself as the dominant player in the consumer wearable health device segment through the Apple Watch's combination of premium design, deep iOS ecosystem integration, and accumulating FDA-cleared health features including ECG, irregular rhythm notification, blood oxygen monitoring, and fall detection. Abbott's FreeStyle Libre CGM system and DexCom's G-series CGMs are the two dominant platforms in the high-growth continuous glucose monitoring segment, collectively serving the majority of the U.S. CGM market with differentiated sensor wear time, accuracy, and smartphone connectivity features.

Key Industry Developments:

• In September 2024, Apple received FDA clearance for sleep apnea detection features in Apple Watch Series 9 and Ultra 2, expanding clinical applications.
• In August 2024, Abbott launched the next-generation FreeStyle Libre 3 continuous glucose monitor with enhanced accuracy and smartphone connectivity features.